The global insulin pen market was valued at $9.9 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 6.1%, reaching $14.1 billion by the end of 2028.
Report Scope
This report thoroughly examines the worldwide market size of global insulin pen delivery technology, enhancing its appeal to stakeholders and readers alike. Current and historical market revenues are estimated based on the type, duration, end user and region.
Report Includes
- An overview of the global market for insulin pen
- Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects specific to insulin pens, accompanied by a comprehensive market share analysis categorized by type, onset time, end user, and geographical region
- A look at the innovations, technological advancements, and the launch of novel products from market players
- Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges and ESG practices in the insulin pen market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players in the industry
Table of Contents
Executive Summary
Growth in this market is fueled by the rising prevalence of diabetes worldwide. As lifestyles change and obesity rates increase, so does the incidence of type 2 diabetes. Additionally, type 1 diabetes rates continue to rise, and both types require insulin for management.
In 2022, the reusable insulin pen segment held the highest market share at about 51.5%, followed by disposable pens at 48.5%.
Reasons for Doing This Study:
The market for insulin delivery systems is a crucial segment in healthcare, pivotal in addressing diabetes, a chronic ailment affecting millions worldwide. These systems encompass a broad array of tools and techniques to simplify the administration of insulin, a hormone vital for regulating glucose levels in individuals with diabetes. Over time, these systems have undergone significant advancements, providing diabetic individuals with more user-friendly and effective methods to manage their health.
Integral components of this market are insulin pens, pumps, syringes, and patches, each offering distinct advantages and functionalities tailored to the diverse requirements of diabetes patients.
Insulin pens are a shining example of innovation in diabetes treatment, transforming the day-to-day management of this chronic disease. Insulin pens, designed to be user-friendly and portable, have become essential tools for millions worldwide who rely on insulin therapy. These pens provide a practical, discreet, and accurate method of delivering insulin, allowing people with diabetes to administer exact amounts effortlessly and enabling them to live more flexible and balanced lives. Insulin pens have improved in form, functionality, and compatibility since their beginnings, establishing a new standard in diabetes care and improving the quality of life for individuals with the disease.
Companies Mentioned
- AstraZeneca
- Biocon
- Boehringer Ingelheim International Gmbh
- Eli Lilly And Co.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis Ag
- Novo Nordisk A/S
- Sanofi
- Viatris Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 78 |
| Published | February 2024 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 9.9 Billion |
| Forecasted Market Value ( USD | $ 14.1 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
